OR WAIT null SECS
© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
October 21, 2021
Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, give advice to any clinicians considering the use of intranasal esketamine for treatment resistant depression.
Drs Harding and Halaris review the requirements health care settings must follow in order to procure, prescribe, and dispense intranasal esketamine as treatment resistant depression therapy.
Two psychiatrists discuss the importance of intranasal esketamine having a Risk Evaluation and Mitigation Strategy (REMS) and how that impacts treatment for treatment resistant depression.
Drs Harding and Halaris evaluate the phase 3 TRANSFORM trial that studied intranasal esketamine as a therapy option for treatment resistant depression.
Two experts examine the impact of targeting the glutamatergic system as therapy for treatment resistant depression.
Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, discuss their thoughts on starting treatment with intransal esketamine and what to expect.
Two psychiatrists review the case of 42-year-old female patient with a treatment resistant depression diagnosis that was prescribed intranasal esketamine.
Drs Harding and Halaris provide an overview of treatment resistant depression, including prevalence and determining a diagnosis.
Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, review a case of a 26-year-old male patient who was recently diagnosed with treatment resistant depression
October 20, 2021
New Drug Application to be submitted for MDD in late 2022, with separate filing for PPD planned for early 2023.